Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease
about
The promise of neuroprotective agents in Parkinson's diseaseAnti-inflammatory drugs and risk of Parkinson disease: A meta-analysisAn overview of clinical pharmacology of IbuprofenNon-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesUse of ibuprofen and risk of Parkinson diseaseInsights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based TherapiesNeuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugsGene-environment interactions: key to unraveling the mystery of Parkinson's diseaseRotenone and paraquat do not directly activate microglia or induce inflammatory cytokine releasePACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in miceNonsteroidal anti-inflammatory drugs are associated with increased neuritic plaquesMicroglia-mediated neurotoxicity: uncovering the molecular mechanismsCyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.Risk for Parkinson's disease among patients with osteoarthritis: a Danish cohort study.Formulations of hormone therapy and risk of Parkinson's disease.Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study.The endotoxin-induced neuroinflammation model of Parkinson's disease.The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research.Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation.Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease.RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells.Death in the substantia nigra: a motor tragedy.Parkin deficiency increases vulnerability to inflammation-related nigral degenerationInflammation and clinical presentation in neurodegenerative disease: a volatile relationship.Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration.Non-genetic factors associated with the risk of Parkinson's disease in Iranian patients.Targets for neuroprotection in Parkinson's diseaseMicroglial ion channels as potential targets for neuroprotection in Parkinson's disease.Innate and adaptive immunity for the pathobiology of Parkinson's diseaseAutoimmune disease and risk for Parkinson disease: a population-based case-control study.Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction.Pharmacological therapy in Parkinson's disease: focus on neuroprotection.Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence.Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug?Parkinson's disease: evidence for environmental risk factors.The role of inflammation in sporadic and familial Parkinson's disease.The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes.Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease.Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability.The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration
P2860
Q21129436-CD017E07-2679-47D4-97AA-19744A4ABE55Q22241651-ECE02050-DECC-444A-88AA-1DB3F76170A8Q23724883-7188F56A-83BC-4B7F-9B23-FCE695AFEE72Q24235107-704BF040-D851-4E6E-862B-75362BEF25DFQ24594751-16F1F72D-51B2-40BC-92BD-4CC5937A6ED8Q26795984-7583A1AD-5EC3-4245-9CAD-826D4933200BQ26801035-694D96E4-A83B-4284-A4FB-59E7391B6DF9Q28388674-00682A72-0A60-4EB2-B259-57DA274C51DFQ28392767-CBDB0F58-109C-4EE8-B101-E42A79B5324BQ28397422-34D57E2C-558A-4751-B6AC-2D67FF037BAAQ28476681-C67BAC5B-2416-41FA-9E97-40CA19BBD999Q29547835-BA8550F1-43A4-4687-BA12-1ACE34B06353Q33836942-B802CFB9-F6F1-4538-B4D4-7814C27A9CD1Q34353167-B40989B6-3F0F-48D8-BD35-3FACCBE38E4DQ34437648-0EC1675E-85A7-419D-8ED3-7B061FD1BCFFQ34505182-332249A3-0EE5-4ACD-AF89-7E299B16C983Q34557246-375AA24C-15C4-4906-BD62-AD2B5AEB4E76Q36048230-C1CC8BCB-B54C-4154-84B8-B4745668969CQ36453886-A5821670-78AC-4232-ACB9-AC5DC489DE12Q36537780-1FA4477D-B0B1-4099-B5C0-11B5D918D03AQ36773965-415466AB-715F-406C-898B-A6115363F1B1Q36847262-30485C7F-5099-433B-BA80-EBE7F7220248Q37015945-589F4FAA-E536-40E6-921B-9AFD73BD7D15Q37069901-DA5E6A84-D541-48BF-922D-A56702136A27Q37241917-A231F78E-93E5-41B8-BB61-C2E3E2896464Q37267160-A48FEB33-27B3-4F0B-96BC-D9BB0018602CQ37302453-A48E27B0-010E-414F-A096-BF4F5AB32DB9Q37322333-45B17C08-7DFB-4597-BA3E-DAE89239D53DQ37401280-79682BC5-2326-47F3-8E94-5DC975F59F78Q37425099-2CCAA1CA-0520-411A-8F86-E6270AB0192BQ37680121-7F060524-3926-4C85-B70A-A221F0C225C9Q37741285-E4EE09D1-5DC1-4F66-AF5F-B5AA5443F484Q37878282-A2BB782D-0EC4-403F-BE54-992B3B660374Q37886152-D8A83421-8A61-47A0-8BA1-9FCCAC944E4DQ38055457-E9C1CBE1-D4A0-4C80-9146-D16C2FED58EBQ38105903-53AD6165-79E1-457A-BE8F-20BD190A1FB5Q38115703-A675F097-B523-4E3A-B950-49EED3CFE865Q38693732-BC3FB94C-578F-4856-9739-35F557519AB3Q38784992-11A45DB2-0A65-4BCC-8114-E5FB937AA2F7Q38860761-523198E8-BC87-493A-9DBC-908A7B6F595F
P2860
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease
@ast
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease
@en
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease
@nl
type
label
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease
@ast
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease
@en
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease
@nl
prefLabel
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease
@ast
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease
@en
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease
@nl
P2093
P2860
P356
P1433
P1476
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease
@en
P2093
Gary M Franklin
Harvey Checkoway
Mary Anne Rossing
Phillip D Swanson
Susan R Heckbert
Terri Smith-Weller
Thanh G Ton
W T Longstreth
P2860
P356
10.1002/MDS.20856
P407
P577
2006-07-01T00:00:00Z